24.60
Schlusskurs vom Vortag:
$24.69
Offen:
$24.39
24-Stunden-Volumen:
558.96K
Relative Volume:
0.74
Marktkapitalisierung:
$1.63B
Einnahmen:
$5.79M
Nettoeinkommen (Verlust:
$-199.61M
KGV:
-8.1728
EPS:
-3.01
Netto-Cashflow:
$-188.48M
1W Leistung:
-5.09%
1M Leistung:
-6.92%
6M Leistung:
+7.85%
1J Leistung:
-2.61%
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Vergleichen Sie CLDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CLDX
Celldex Therapeutics Inc
|
24.60 | 1.64B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Underweight |
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Whats Radiant Logistics Incs historical returnQuarterly Market Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Update Recap: Does Celldex Therapeutics Inc stock benefit from AI growthMarket Rally & AI Powered Market Entry Strategies - baoquankhu1.vn
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Weak Trading Performance - Yahoo Finance
Will Celldex Therapeutics Inc. benefit from government policyJuly 2025 Summary & Stepwise Trade Signal Guides - mfd.ru
Celldex Therapeutics (CLDX) Investor Outlook: Analysts See Over 100% Upside Potential - DirectorsTalk Interviews
Growth Report: Will Celldex Therapeutics Inc benefit from geopolitical trends2025 Pullback Review & Consistent Income Trade Recommendations - baoquankhu1.vn
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness - Sahm
Will Celldex Therapeutics Inc. stock hit new highs in YEARWeekly Stock Recap & Pattern Based Trade Signal System - mfd.ru
Day Trade: cờ tướng họcEarnings Growth Summary & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Large Growth in Short Interest - MarketBeat
Pullback Watch: Whats the fair value of Celldex Therapeutics Inc stockWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn
Reassessing Celldex Therapeutics (CLDX) Valuation As Shares Trade At A Discount To DCF Estimates - Sahm
Value Recap: Is Celldex Therapeutics Inc stock resilient to inflationFed Meeting & Smart Allocation Stock Tips - Bộ Nội Vụ
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Unpacking a 107.86% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Celldex Therapeutics SVPs Engage In Heavy Transactions - AOL.com
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 7.5%Here's Why - MarketBeat
Market Pulse: Can Celldex Therapeutics Inc disrupt its industryMarket Rally & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Can Celldex Therapeutics Inc disrupt its industry2025 Geopolitical Influence & Reliable Price Action Trade Plans - baoquankhu1.vn
How Advancing Antibody Pipeline And 2027 Cash Runway At Celldex Therapeutics (CLDX) Has Changed Its Investment Story - Sahm
Will Celldex Therapeutics Inc. stock see insider buyingPortfolio Risk Summary & Detailed Earnings Play Strategies - ulpravda.ru
Will Celldex Therapeutics Inc. stock deliver better than expected guidanceQuarterly Profit Report & Advanced Swing Trade Entry Plans - Улправда
Why Celldex Therapeutics Inc. (TCE2) stock could be top winnerJuly 2025 Chart Watch & Fast Entry High Yield Tips - Улправда
Is Celldex Therapeutics (CLDX) Pricing Reflect Its DCF Upside After Recent Share Swings - Sahm
Will Celldex Therapeutics Inc. stock attract more institutional investors2025 Market Overview & Precise Swing Trade Alerts - Улправда
Can Celldex Therapeutics Inc. stock deliver surprise earnings beatStop Loss & Daily Growth Stock Investment Tips - Улправда
How Celldex Therapeutics Inc. stock trades during market volatility2025 Analyst Calls & Fast Entry Momentum Trade Alerts - Улправда
Is Celldex Therapeutics Inc. stock a good choice for value investorsMarket Sentiment Summary & Smart Allocation Stock Reports - Улправда
Chronic Spontaneous Urticaria Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company - Barchart.com
Celldex Therapeutics Builds Momentum Around Barzolvolimab And Bispecific Antibody Programs - RTTNews
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Celldex Therapeutics (CLDX) Stock Analysis: Biotechnology Innovator with Over 100% Upside Potential - DirectorsTalk Interviews
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% HigherShould You Buy? - MarketBeat
Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9% - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Strong Buy Ratings and Nearly 96% Upside Potential - DirectorsTalk Interviews
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 - Insider Monkey
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely - Yahoo Finance
Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX - MarketBeat
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Celldex Therapeutics (CLDX): Assessing Valuation After a Recent Share Price Uptick - Sahm
Income Plays: How sustainable is Celldex Therapeutics Inc. stock dividend payoutGDP Growth & AI Powered Trade Plan Recommendations - Улправда
Will Celldex Therapeutics Inc. stock outperform value stocksJuly 2025 Levels & Weekly High Potential Stock Alerts - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform growth indexesJuly 2025 Spike Watch & Verified Swing Trading Watchlists - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform tech sector in 2025Weekly Trade Summary & Low Volatility Stock Suggestions - Улправда
How Celldex Therapeutics Inc. stock performs after earningsInflation Watch & Stepwise Entry and Exit Trade Signals - Улправда
Aug Summary: Will Celldex Therapeutics Inc. stock see insider buying2025 Momentum Check & Real-Time Buy Signal Alerts - Улправда
Barclays Maintains Celldex Therapeutics (CLDX) Underweight Recommendation - Nasdaq
Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $24.00 at Barclays - MarketBeat
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):